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This paper focuses on the transformation of a recently promoted medicinal plant named 
Artemisia annua L. For over 2000 years, the Chinese have used A. annua as a herbal tea 
preparation against malaria. Pharmacological studies led to the isolation of artemisinin as the 
principal anti-malarial compound. Since 2001, the World health Organisation (WhO) has 
recommended artemisinin-based combined therapies (‘ACTs’) for the treatment of malaria – 
novartis is the leading actor to extract the compound in tablet form. in the 1990s, A. annua 
was introduced to Tanzania. Beside the local plant-based promotion of Artemisia-tea as an 
efficient, inexpensive natural practice to treat malaria, Tanzania hosts influential actors who 
seek to commercialise the plant. By following the biography of the Chinese medicinal plant, 
its global transfer, production, marketing, distribution, consumption, and its transformation 
to a highly demanded commodity, the paper critically reveals the dialectics and reciprocities 
between different actors and their relation to existing powerful reference systems (such as 
WhO, Pharmaceutical industry).
Keywords: Artemisia annua L., artemisinin, Tanzania, ACT, effectiveness, social life of 
medicines
“Artemisia (Artemisia annua) is a seemingly simple, though versatile, medicinal 
plant suddenly at the heart of international attention. It was long a traditional 
remedy for a variety of ills. But by virtue of the extraordinary qualities of a puri-
fied extract, artemisinin, it is now a key player in global efforts to help control 
malaria, particularly in Africa where it is a particular scourge. In doing so, it is 
following in the legendary footsteps of quinine, also a plant derivate (…), and 
has become - at least for the present - one of the most important medicinal 
plants in the world.”                                                  
(Dalrymple, 2008: 57)
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Introduction
Malaria is the most important parasitic disease of mankind. Each year, malaria causes 
disease in approximately 515 million people and kills between one and three million 
people, the majority of whom are children in sub-Saharan Africa (Snow et al., 2005). In 
Tanzania, we see 14 to 18 million new malaria cases and up to 125 000 malaria-related 
deaths every year.1  Researchers have pointed out that the most plausible single factor 
contributing to this staggering number is the resistance to widely available, low-cost 
antimalarials. During the past few years, traditional single drug treatments (known as 
monotherapies such as chloroquine) have lost appreciable effectiveness and are currently 
replaced by a new generation of antimalarials: artemisinin-containing combination 
therapies, ‘ACTs’ (White, 2004; Arrow et al., 2004; Namdeo et al., 2006). 
ACTs derive from the Chinese medicinal plant Artemisia annua (its ancient Chinese 
name is qinghao, blue-green, fragrant herb), a species which is known worldwide 
for its antimalarial properties (Wright, 2002; Hsu, 2006a+b).2 For over 2000 years, 
the Chinese have used what is commonly called Sweet wormwood as a herbal tea 
preparation for treating periodical fevers (indicative of the paroxysms of malaria) 
and other ‘heat syndromes’ (Guo Qiao et al., 1994; Valecha and Tripathi, 1997; 
Mueller et al., 2000).3 The fresh juice soaked by the entire plant was found to be most 
effective in relieving chills and fever when used in large dosage. Artemisia´s historical 
usage to ‘clear damp heat’ associated with malaria has then been confirmed with 
modern pharmacology (Chen and Chen, 2004; Hsu, 2006a: 667). The clinical utility 
of a component and extract from the Chinese plant – artemisinin (qinghaosu) – has 
globally stimulated interest in traditional plants as potential sources of new antimalarial 
drugs. Artemisinin and its derivates have a very rapid onset of action against the most 
virulent form of malaria, P. falciparum, and have been found to be the most rapidly 
acting of all antimalarial drugs (Haynes, 2006).4 As the key-ingredient in the leading 
treatment for malaria is an extract of an ancient medicinal plant, the (re-)discovery of 
A. annua reveals something that Dalrymple (2008:7) prospects as a “golden triangle” – 
an interaction between traditional medicine, modern medicine, and science. The fact, 
that artemisinin-based combination therapies are ‘ancient’ in its use and ‘modern’ in its 
formulation shows the transformation potential of the plant itself: “[...] the medical 
rationale for dispensing these medications has been shaped by commercial demands 
in ways that have worked toward transforming the formerly scholarly Chinese medical 
tradition […] into a consumer-near and popular ´folk medicine`” (Hsu, 2009: 111). 
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Pic.1 1 Artemisia annua in Tanzania (Photo by C.M.)
The Chinese plant was transferred to other socio-cultural contexts and now plays an 
important role in East Africa (Heemskerk et al., 2002). In the early 1990s, Artemisia 
(as an artemisinin- rich genetic variety) was introduced in Tanzania, where experts 
concluded that the production of the medicine locally was a viable option in combating 
malaria. Due to continuously developing resistance against widely used malaria drugs 
in the country, the Tanzanian Ministry of health has been forced to call for a shift in 
treatments. National health authorities then considered artemisinin-based remedies as a 
promising approach for addressing the disease at the primary health care level (Kachur 
et al., 2006; MoH, 2008). The use of Artemisia´s semi-synthetic medicines have widened 
the range of treatment in Tanzania and numerous studies have demonstrated their 
therapeutically potential (Yeung et al., 2004; Nosten and White, 2008). 
Besides this, also the Artemisia-leaves become increasingly used in the treatment 
of malaria. Tanzania hosts a wide spectrum of researchers and stakeholders who are 
seeking for alternative Artemisia - therapies, which are efficient, inexpensive, accessible, 
and widely available in the country, especially for the rural population. Thus, there is no 
single usage but a range of treatment possibilities provided by the plant-ingredients.  
As has been widely reported, pharmaceutical concerns world-wide are conducting 
research into this medicinal plant (Bhakuni et al., 2002; Bosman and Mendis, 2007). 
While there has been overloading information available on A. annua and its chemical 
derivates, the antimalarial activity of artemisinin, the development of ACTs, agricultural, 
technical, and economical outcomes of the plant, considerably less has been written on 
its acceptance, adoption, and most important, cultural effectiveness – especially in regard 
to its global transfer.5 
Following its trajectory, meaning and use, the Artemisia plant became my main object 
of research. I traced the plant into multiple sites in Tanzania, where it has been planted, 
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therapeutically used, and commercially produced. My research draws on ethnographic 
fieldwork undertaken between 2006 and 2008.6 During the research, special attention 
was given to the potential of Artemisia as a self-reliant treatment for malaria including 
local production practices followed by the possibilities for using herbal infusions from 
the plant leaves (Hirt 2000, 2001; Hirt et al., 2004; Hirt and Lindsey, 2006a+b; De 
Ridder et al., 2008: 303).7 The feasibility of using the traditional formulation of Artemisia 
were investigated as a more affordable and accessible option for the treatment of malaria 
in poor and remote areas. Challenges, advantages, and renewal were documented that 
people face through the introduction of this new remedy; contemporary dynamics and 
transformations of medical knowledge gained through Artemisia were also explored. 
Given the fact that several actors are linked with Artemisia annua, multiple forms 
of adoption, consumption and (re-) productions of the plant exist. A number of 
plant-based products (such as herbal tea infusions, herbal pills or artemisinin-based 
pharmaceuticals) are found – depending on who is interested in influencing the 
acceptance of Artemisia. The classification of the plant itself is subject to change. A 
variety of – often conflicting – attributes such as ‘natural’F, ‘traditional’, ‘modern’ or 
‘commercial’ given to the plant had a strong influence on the legitimisation of treating 
or healing practices with Artemisia. Actors such as non-governmental organisations 
or churches – primarily the international NGO called Action for Natural Medicine 
(Anamed) – who push the application and utilisation of Artemisia- tea formulation based 
on the Chinese pharmacopeia (Willcox et al., 2009: 104) – would classify Artemisia as 
a ‘natural’ plant-based medicine (in the Swahili language dawa ya asili), emphasising 
the fact that it has been extensively studied, scientifically tested, and proven. They 
endorse it as an alternative to pharmaceuticals and promote it in opposition to the 
locally available ‘traditional medicine.’ Traditional healers, however, would consider 
Artemisia a ‘traditional’ medicine (dawa ya kienyeji) and incorporate it into their materia 
medica. Due to significant similarities between the Chinese variety and the indigenous 
Artemisia-plant (Artemisia afra), the new remedy was highly accepted among healers. 
Likewise, malaria patients embraced the new treatment, especially in those areas where 
the use of indigenous plants has always played an important role in addressing malaria 
(Gessler et al., 1995: 131; Maregesi et al., 2007). Other actors in Tanzania who use 
Artemisia in commercial-scale cultivation would classify the plant-based products as a 
European (dawa ya kizungu) or ‘modern’ medicine (dawa ya kisasa). As a consequence of 
different naming and marketing strategies Artemisia becomes a very versatile plant and 
occupies different niches. Several actors are pushing the proliferation of Artemisia and 
its varying products like the Artemesia-tea, the efficacy of which is still controversial as 
Willcox et. Al. (2009) points out:   
“[...] There has been much debate as to whether it is appropriate to recommend the 
use of A. annua herbal teas for the treatment of malaria. At one end of the spectrum, 
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commercial growers of A. annua and manufactures of artemisinin have claimed that 
it would be `criminal´ to promote the use of A. annua teas because they contain `sub 
therapeutic doses´ of artemisinin, which in theory could lead to the evolution of para-
sites resistant to artemisinin. [...] At the other end of the spectrum, Anamed replies that 
it would be criminal not to provide A. annua to remote communities that do not have 
any other treatment of malaria. health care infrastructure is lacking in most of the 
areas worst affected by malaria, making it impossible to distribute drugs to those who 
most need them” (Willcox et al., 2009: 107). 
The discussions on the usage of Artemisia in this form are as divergent as local discourses 
on the use of an artemisinin-based pharmaceutical in Tanzania, as demonstrated in the 
following part of the paper.
The drug in question is called Coartem® and was designated by the Tanzanian 
Ministry of Health and Social Welfare as a first-line therapy nationwide. In 2005, 
Tanzania began the process of initiating a second treatment policy in change, which 
culminated in the large scale public sector deployment of artemisinin-based drugs 
(NMCP, 2007). Due to long-lasting price negotiations among the Global Fund to 
Fight AIDS, Tuberculosis and Malaria (GFTM) and Tanzania’s Ministry of Finance, 
the Swiss company Novartis completed drug delivery in 2006 (Novartis, 2010). Much of 
the procurement was subsidised and the drug almost entirely (80%) distributed through 
the public sector; leading to a significant shortage of artemisinin-based combination 
therapies in the private sector (Wolf und Derriennic, 2005:11). There is still limited 
availability of the drug outside the public sector and the phase of equating of supply and 
demand of Coartem® remains a challenge (Dalrymple, 2008: 32, 45). In 2006, among 
14-19 million malaria patients, less than six million patients had access to the new drug 
(Freyhold, 2008:2f ). In Tanzania, 40-60% of people seek treatment for malaria from 
private vendors, such as pharmacies (duka la dawa baridi), drug shops and general stores 
(Njau et al., 2008:1). As artemisinin-combination drugs are typically sold at retail prices 
20-40 times those of common alternatives (such as monotherapies), restricting their 
uptake by consumers, particularly in rural areas (Kachur et al., 2006). As a result, most 
retail sector antimalarial consumers continue to use therapies for which resistance has 
been proven. It is widely acknowledged that access to quality treatment is insufficient in 
many settings. At local community level, the affordability or availability of antimalarial 
drugs is only a few among a number of factors influencing effective treatment. As shown 
in the following case study, malaria patients also struggle with unpleasant side-effects. 
Tunaogopa dawa hii – we fear this medicine!
“All drugs are `problem´ drugs…What makes a drug a problem is not so much 
its inherent pharmacological risks, but the way in which it is used. It is impos-
sible to talk about the ´safety` of medicines as if it was a laboratory problem. In 
the wrong hands or at the wrong time, even the most carefully quality-controlled 
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medicine becomes transformed from a life-saver to a life-threatener.”
Chetley and Gilbert (1986:3)
When I visited Jonasi Daudi8 in 2007, he held up, in one hand, a partially fractured 
packet of dawa ya mseto, which means ‘mixed medicine’ in the Swahili language and 
refers to the new antimalarial combination drug called ‘ALU’, also known as Coartem®. 
In his other hand was a set of pictures that showed remarkable skin irritations on the 
body of his deceased wife Bahati, a well-known woman in the outskirts of Musoma – a 
small town in the North-western part of Tanzania. I got to know her as well when I 
stayed in the same area. I heard about Bahati´s death through the grapevine and went 
to find her husband to express my condolences. He shared the tragic circumstances 
of his wife’s death with me. According to him, after having been tested positively for 
malaria, Bahati got a prescription for 24 Coartem®-tablets, which she was supposed to 
take for three days. Shortly after having ingested the first dosage, Bahati’s skin became 
increasingly itchy.
“My wife started to sweat, she felt miserable and expressed doubts (mashaka) on 
this medicine”, Jonasi recalled. He went on: “she thought her body would need 
time to get used to the new drug. But after having taken another four tablets, 
Bahati complained about palpitation, she had chills (kitapo) and her skin started 
to itch strongly (ngozi yake ilianza kuwasha sana). My wife´s started to develop 
blisters (ngozi yake ilianza kutoa malenge lenge) and it felt like burning fire (ngozi 
yake ilihisi kama ime chomwa na moto). When she started to scratch her skin, 
it began to peel off (ngozi yake ilianza kubabuka), first on the scalp (ngozi ya 
kichwa) and then on the entire body. Whenever my wife tried to move in her 
bed, the skin would stick to her kanga9 and peel off, causing her terrible pain.”
Bahati was moved to the local hospital in Musoma, but her condition got worse. 
Within a few days, her skin peeled off; she lost consciousness (hakuwa amezirahi kabisa), 
and collapsed. The doctors diagnosed that she developed allergic reactions caused by 
the tablet ingredients.10 They tried in vain to stop the skin irritations with cortisone 
injections and Piriton allergy tablets, but Bahati died aged 41.
In the photographs that documented her illness episode at the hospital, Bahati looked 
so blemished and deformed; I could hardly recognise the strong and portly woman I used 
to know. The pictures gave an insight into the extent of her suffering. Her sudden death 
not only shocked people in her community, but provided a basis for long lasting rumours 
about the medicine she had been prescribed. Bahati’s widower, family members, friends, 
and neighbours believed the side-effects (madhara) of the new drug to be the cause of 
her death. Discussions started on Bahati’s usage of a ‘bad medicine’ (dawa mbaya sana) 
and the complications she faced. Candidly expressed statements such as: “this medicine 
causes allergic reactions” (madhara ya dawa) or: “we fear this medicine” (Sw: tunaogopa 
dawa hii) contributed to the doubts in the Musoma community about the drug.
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As issue became more public and ‘hot’, Jonasi Daudi was impressed upon by the 
hospital by the hospital not to regard the death of his wife as a consequence of her 
consumption of Coartem®. When I met Jonasi a few weeks later, he would insist his wife 
must have been poisoned by one of her family members (“mtu fulani alikuwa amempa 
sumu”) and the link to the drug was never mentioned again. Other family members of 
Bahati confirmed that her illness episode now was meant to be kept a secret (“ilipangwa 
kutunzwa kama siri”).
I was aware that the identification and evaluation of pharmaco-therapeutic side effects 
is mediated through social and cultural constructs (Etkin, 1988; Kamat, 2009). Yet, I 
decided to direct my attention to the dynamics of drug distribution and marketing in 
order to find out who might benefit or lose out from a negative message being spread 
about the pharmaceutical product Coartem®. The incidents and reactions of people in 
my immediate environment gave fuel to my growing concern. An ongoing discourse 
emerged as numerous other patients expressed their doubts and resistance to Coartem®. 
Mostly common were local terminologies referring to a “loss of strength” (literary: 
nguvu inashuka), such as “Coartem® tires you” or “causes extreme exhaustion” (ALU 
inachokesha sana). Similar to Bahati’s case, also other patients reported of having had 
strong physical reactions they believed were caused by the medicine in question. Among 
them were general skin irritations (tatizo la ngozi):  “it results in mouth ulcers and rashes 
on the body” (inaleta vipele mdomini mapele mwilini) or “there is itching all over the 
body” (kuwasha washa). Those statements remained harmless in comparison to local 
perceptions on ALU such as “people lose their lives” (Sw: watu wanapoteza maisha) or “it 
kills” (Sw: inaua kabisa), that circulated only a year after the new drug was implemented 
in Tanzania.
My investigations into the use of Coartem® among medical authorities raised my 
awareness of the economic interests at play behind the scenes. It became obvious that the 
questioning of a highly promoted and promising medicine was almost impossible. The 
medical staff at the hospital in Musoma retracted their earlier statement on ALU side 
effects; and the Tanzanian Ministry of health as well as representatives of the national 
Malaria Control Programme claimed that no serious side effects ever occurred since the 
introduction of the drug. A veil of ignorance and silence seemed to have descended on 
the case of Bahati and other patients, contributing to my understanding of how delicate 
research about medicines can be. The lack of transparency around the handling and 
control of Coartem® further supported this perspective. I merely witnessed people’s 
reactions to taking the drug and how their voices were ignored or silensed. 
As I am aware of the subjectively perceived efficacy of medicines, my paper does not 
seek to prove whether this medicine can be harmful or not. My focus is on the question 
of how policymakers use claims about safety in order to secure their control over the 
discourse on antimalarial treatment and maintain a monopoly over its production. To do 
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so – by using its biography – I will briefly describe the processing of the Artemisia plant 
into a pharmaceutical drug in the following section. My discussion here leads to one of 
the key points in the paper: that medicines are powerful technical devices and cultural 
symbols, which can acquire ‘a life of their own’ in society. As vehicles of ideology and 
perceived sources of efficacy, they impact peoples’ thoughts and actions and influence 
their life (Van der Geest, Whyte, and Hardon, 1996). 
The social life of a medicine: the rise to prominence of Artemisia 
annua L.
Van der Geest, Whyte, and Hardon (ibid: 156ff ) used a popular anthropological 
metaphor to capture the social and cultural dimensions of medicines: Appadurai’s 
concept of “Social life of Things” (1986:57). Studies in medical anthropology illustrate 
pharmaceuticals as social and cultural phenomena by following their ‘life cycle’ from 
production, marketing, distribution, purchasing, consumption, and finally their efficacy. 
Each life stage is characterised by a specific context and particular actors; it has a “regime 
of values” expressed in distinctive sets of ideas about medicines. This concept also applies 
for the social life of the Chinese medical drug qinghao as particular actors are involved 
in every step of the drug-production chain – from seed planting to the processing of 
artemisinin, to manufacturing and distribution of the finished pharmaceutical:
 
Pic.1 2Artemisia annua from the Chinese materia medica (by Willcox 
et al., 2004: 103)
Within the production and marketing phase, the primary social actors were Chinese 
scientists, health authorities, and international pharmaceutical companies. One of 
the main biographical marking points of the drug was its ‘re-discovery’ in China. The 
transformation of the plant to a highly demanded commodity was part of a complex 
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historical process that began with the systematic screening of the Chinese materia 
medica to discover new drugs with antimalarial property. In 1972, the plant constituent 
artemisinin was isolated and subsequently identified as a sesquiterpene-lactone found 
to be effective against malarial parasites (Klayman, 1985; Bökemeier, 2006; Hsu, 
2006a). Since then, the chemistry of the compound, the pharmacology, and the clinical 
applications of artemisinin and its synthetic derivates have been widely explored and 
analysed (Bilia et al., 2002). In fact, they became the most potent and rapidly acting 
anti-malarial drugs ever discovered (White, 2008:332; Willcox, 2009:103) – results, 
that marked a starting point for pharmaceutical industries to hunt, commercialise, and 
patent the plant-based derivates.
Pic.1 3 Commercial Artemisia-plantation in East Africa (Photo by 
C.M.)
Another prerequisite to transform the Artemisia plant was the development of a genetic 
variation as it is recognised that artemisinin content is affected by geographic and seasonal 
variations, growing conditions and plant breeding (Hirt, 2001; Laughin et al., 2002; Liu et 
al., 2006). For this reason, the science of agricultural cultivation of Artemisia to maximise 
artemisinin yields became well-developed. The company Médiplant Switzerland produced 
an exceptionally high yield of artemisinin, the hybrid Artemis, one of the best genetic 
varieties for lower latitudes to successfully achieve commercial exploitation of Artemisia in 
tropical countries such as Tanzania (De Ridder et al., 2008: 305).
Furthermore, pharmacological and clinical evidence was needed to commercialise 
Artemisia-plant based derivates. The World Health Organisation as a powerful authority 
provides leadership on global health matters; articulates evidence-based policy options, 
monitors, and assesses health trends. By 2001, WHO had officially recommended 
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artemisinin-based combination therapies as the anti-malarial of first choice, preferably 
the drug Coartem® produced by the Swiss company Novartis, who holds the patent 
to the drug (Dalrymple, 2008:12). In a unique collaboration WHO and Novartis 
constructed special claims about the safety and effectiveness of this medicine which 
are used to justify its registration and marketing. In addition to its efficacy, safety and 
tolerance profile, Coartem® is expected to “increase the likelihood of patient compliance 
with the drug regimen” (WHO, 2001: 15, 23).
Although several other artemisinin-containing compounds have been registered, in 
Tanzania no fewer than 31, Coartem® became the leading therapy and a mainstay for 
malaria treatment worldwide (Kachur et al., 2006: 2; Dalrymple, 2008: 13). The number 
of developing countries adopting the combination-drug as the first-line treatment for P. 
falciparum has grown significantly, reaching a total of 77 by 2008 (WHO, 2008:16). While 
a number of firms are known to produce artemisinin-based monotherapies, the ranks 
of those producing ACTs have been more limited: at the international level, Novartis 
has been the major source (Dalrymple 2008: 17). As Novartis is the sole pharmaceutical 
company that manufactures this combination drug, and as it has been internationally 
criticised, it has had a long-time monopoly on its production (MSF, 2004). Through an 
international partnership, WHO and Novartis claim to achieve cure rates of over 96% 
and confirm that their products are wholesome and effective. Such established scientific 
claims boost the production of Coartem® in international competition. 
Future demand for Coartem® is anticipated 100 million treatments per annum 
(Novartis, 2010).11 In order to produce these quantities, immense volumes of raw material 
extracted from Artemisia are required. As the leading global supplier, Novartis has 
established an industrial partnership with the holding company Advanced Bio-Extracts 
Ltd (ABE), now Botanical Extracts Ltd (BEEPZ), to significantly increase agricultural 
cultivation of Artemisia and extraction of artemisinin. Together with their subsidiaries 
East African Botanicals (EAB) in Kenya/ Uganda and African Artemisia Ltd in 
Tanzania, around 1,700 ha Artemisia-plants have been cultivated in 2008 (Cuttler, 2008).12 
Although Novartis claims to improve local economies in East Africa by producing the 
raw material there, the profit for local actors in Tanzania is relatively poor. Access to 
technology of artemisinin-extraction methods is highly controlled. As Artemisinin-
based monotherapies are explicitly discouraged and forbidden, local pharmaceutical 
companies are no longer involved in manufacturing the medicine in tablet form. 
Furthermore, (small-scale) farmers – who play an important role in the production chain 
of Coartem® – experience a strong discrepancy between production volume and their 
compensation for it. In Tanzania, up to 4,700 farmers are involved in the Artemisia-
production (TechnoServe, 2005). But due to a high price fluctuation of the commodity 
artemisinin, the production-marketing chain got affected – sufferers being mainly 
farm producers of Artemisia, who received low prices (see also Dalrymple 2008: 46), or 
experienced total loss of income as it was the case in 2007.13 Moreover, knowledge on 
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the Artemisia-plant is retained, respectively wrongly handed on Artemisia-growers. The 
fact that some farmers were taught to cultivate an insecticide (dawa ya kuua wadudu), 
rather than a medicinal plant, and the fact that they are provided with protection clothes 
for harvesting process to avoid contamination with what they are told is poison (-enye 
sumu), indicates a powerful control and governance of knowledge on the plant. Those 
results are leading to a reasonable suspicion that the personal usage of the plant-leaves 
may be systematically suppressed. 
Pic.1 4 Three month-old Artemisia-field, commercial cultivation 
(Photo by C.M.)
Pic.1 5 Small-scale farmer cultivating A. annua (Photo by C.M.)
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Pic.1 6 Artemisia-raw material ready for crude extraction (Photo by 
C.M.)
Pic.1 7 Coartem® in a Tanzanian health facility (Photo by C.M.)
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As briefly described, many steps are needed to transform A. annua from a medicinal herb 
to a registered medication. After a medicine has come into the hands of a consumer, it 
reaches the final stage of its life-cycle: the pharmaceutical efficacy is its ultimate and 
decisive life stage. It is one thing to demonstrate the clinical efficacy of antimalarials 
in controlled environments, and quite another thing to ensure their effectiveness when 
they are deployed under ‘real-life conditions’ (Amin et al., 2004; Yeung and White, 
2005: 121). As Kamat (2009: 301) rightly states, at a time when the literature on drug 
resistance and the pharmacological efficacy of antimalarials is growing, the relative lack 
of attention to social and cultural aspects of their effectiveness is a cause for serious 
concern.
“if the full benefits of ACT [Artemisinin-Combined-Therapy] are to be realized in 
Africa, then international donors and African governments must continue to actively 
tackle the broader political, social, economic, legal, and cultural challenges to successful 
implementation. Rather than only focusing on efficacy, it is time to emphasize these 
contextual factors that affect programme effectiveness. having a better understanding 
of these influences on malaria treatment policy formulation and implementation, and 
applying this understanding to improving health service delivery, should facilitate the 
provision of effective malaria therapy in Africa.”  Durrheim and Williams (2005: 
178)
Ethnographic studies of cultural perceptions of antimalarials provide useful 
perspectives not only on how people negotiate the identity of a febrile illness, 
but how to understand and interpret the efficacy of existing antimalarials 
(Kamat 2009: 293). Numerous studies in medical anthropology have argued that 
efficacy is embedded in culturally specific expectations of the healing process, and that 
is has biological and behavioural dimensions, both of which are equally important 
(Nichter 1992; Whyte et al., 2002).14Anthropologists look at medicines as social and 
cultural phenomena. They do not overlook their therapeutic function, but want to draw 
attention to aspects that usually are overlooked: their social, cultural, economic, religious 
and emotional effects. Medicines are a good example of valuable things that assume a 
wide variety of meanings, far beyond their material (chemical) properties. In the social 
lives of medicines, themes such as power and inequality, belief, economic rationality and 
globalisation merge (Van der Geest and Hardon, 2006: 1, 4).
Conclusions
“Given the fact, that medicines are not mere things but are socially and culturally con-
stituted artefacts anchored in both local and global histories, medicines come to reflect, 
and also shape, any changes in societies and cultures in which they circulate. They tell 
not merely reflective stories to be interpreted but are themselves active players in a field 
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that situates people of particular times and places within wider global trends” (Hsu, 
2009: 112). 
There have been more clinical trials on artemisinin and its derivates – as monotherapies 
and fixed combinations – than with any other antimalarial drugs (Yeung and White, 2005: 
121). As argued in this paper, the total drug effect of Coartem® – usually documented 
with observed treatment in randomised controlled trials – is not only formed by medical 
results, but rather based on different pillars. Discourses surrounding antimalarials 
remain a dominant framework for the judging and evaluation of their effectiveness on 
a community level. The perceived effectiveness is often dependent on several aspects, 
including community awareness, prescribed drug policy, shifts in national policy on 
(newly) recommended antimalarials, as well as the complex configuration of the local 
medicine market. Such factors contribute to the acceptance or rejection of medicines. 
Experiences and rumours about Coartem® side effects, such as the incident described 
earlier had a particular influence on people’s acceptance of the drug. As it was the case 
with the first fixed combination-therapies (such as sulphadoxine-pyrimethamine), 
perceptions of Coartem®’s efficacy were reflected in statements about the calls made 
by policy makers to regularly replace antimalarials, which were negatively interpreted 
(see Mubyazi et al., 2005; Kamat, 2009: 294). Access and cost (Wolf and Derriennic, 
2005) were additional crucial components of the drug’s reception. Assumptions about 
Coartem®’s efficacy was closely tied to the perceived costs of the malaria episode.
In addition are considerable logistical costs (Njau et al., 2008). The high cost of 
Coartem® has been a fundamental obstacle to implementing changes in malaria 
protocols as it maintains a dependence on bilateral assistance and multilateral subsidy 
programs, detracting from more sustainable solutions (Dalrymple 2008: 37, 45). Another 
set of problems involves the fake and/or sub-standard artemisinin-drugs (Willcox et al., 
2004: 3; Dalrymple, 2008: 24). As patients are supposed to ingest four Coartem® tablets 
twice a day for three days, adherence remains another challenge. Even if the correct 
regimen is received, there is concern that patients will not adhere to the recommended 
drug schedule, resulting in treatment failure and encouraging the development of drug 
resistance (Yeung and White, 2005:121ff ). In summary, levels of use were generally 
low as widespread public-sector deployment of artemisinin-containing drugs has been 
constrained by their relatively high cost and limited global supply, access, as well as 
some lingering concerns about safety (Mutabingwa 2005: 307; Kachur et al., 2006: 2; 
Dalrymple, 2008: 7). 
As Yeung and White (2005: 133) emphasise, “there has been considerable interest 
and concern in translating antimalarial efficacy into effectiveness, when drugs are taken 
unsupervised in ‘real-life’ settings in malaria-affected communities.”  The importance 
of understanding of how those medicines are used in the community, and how their 
use might be improved, have been conceived and reflected in numerous studies. 
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Nevertheless, malaria has a serious impact on health and economic welfare in the 
tropical world.
This paper lends itself to the concerns about questions of safety and efficacy from 
a biomedical view, and their limitations from an anthropological view. It argues that 
there is no singular, universal perception of (curative) effectiveness, as efficacy must be 
viewed as something that is essentially negotiated (Waldram, 2000:603). A lot more is 
at stake in malaria control than the rolling out of highly subsidised ACTs. Integrating 
knowledge of practices surrounding consumption of preferred antimalarial treatment 
possibilities can be immensely valuable in improving the effectiveness of malaria 
control interventions (see also Kamat and Nyato, 2010:8). By taking a closer look at 
the production and supply-chain of Coartem®, and by exploring alternative ways for 
patients to become independent in malaria treatment (through the whole plant leaves 
as a first-line home treatment), I have come to deeply question the overall effectiveness 
of its use and critically reveal the production of evidence as shaped by influential actors. 
No policymaker can afford to overlook the complexity of medicines or the way in which 
they impinge on the quality of provision and use. As I tried to show, power is exerted for 
financial and social benefit, as influential actors claim to be philanthropists. Coartem® 
is claimed as the hard core of good health care but in its singular manifestation it has 
blocked progress for other possibilities of how to consume this helpful remedy. 
The aim of any effective malaria management strategy is supposed to provide a simple 
and inexpensive treatment that can be applied effectively in most settings (De Ridder et 
al., 2008: 303). A significant proportion of Tanzanians cannot easily access basic health 
facilities because of geographical or economic barriers, even though they recognise 
their illness as malaria. The inadequacies of health services – inequitable distribution, 
high costs, or inaccessibility – and the high burden of malaria in rural communities 
are among the major reasons for patients’ interest in self-treatment. The simple herbal 
infusion of A. annua is an inexpensive, first-line home-treatment in areas with limited 
medical facilities. It rapidly reduces malarial parasites and symptomatic signs of malaria 
in areas with multi-drug resistance to orthodox malarial treatments and can therewith 
reduce the morbidity and mortality associated with severe malaria occurring through 
delayed treatment. Furthermore, through the suffering of fewer bouts of malaria it will 
allow communities to be more economically productive as the impact of the Artemisia 
introduction goes beyond medical improvements. As Elisabeth Hsu (2006: 669) argues, 
Artemisia´s importance for the future of medicine may not lie so much in its effectiveness 
as a modern pharmaceutical but in its potential to revolutionise the organisation of 
antimalarial healthcare in those areas where malaria is endemic and the Artemisia plant 
could be widely accessible.  
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Notes
Endnotes
1 Malaria accounts for 30% of the national disease burden, 43% of under-five 
outpatient attendance, 35% of under-five hospital admissions and 37% of 
under-five hospital deaths (NACP 2008). 
2 The genus Artemisia comprises more than 400 species, most of them 
having an aromatic and bitter taste. Botanically, Artemisia is a vigorous 
weedy annual which is single-stemmed and ranges in height from one to 
three metres. As a member of the Asteraceae family, the genus is native 
to China. Now widespread, being found in Vietnam, Russia, Japan, North 
and South America, and South Africa and cultivated in East Africa for the 
pharmaceutical industry (Willcox et al., 2004: 43; Dalrymple, 2008:14). 
3 First documented in “Prescriptions for Fifty-two ailments” existing from 
the Han Dynasty of 168 BC; A. annua was described as a treatment of 
hemorrhoids. Later in 340 AD, Ge Hong, author of the “handbook of 
Prescriptions for emergency Treatment” described the herbal infusion as an 
effective treatment of intermittent fevers. In the 16th century, Li Shizhen, 
writer of the “Classified Materia Medica”, stated that A. annua was a remedy 
for malaria associated with fevers and chills. The Traditional Chinese 
Medicine recognised Artemisia as having cold and cooling properties useful 
in relieving heat syndromes (fevers) with a detoxicant effect (Yu and Zhong, 
2002; Hsu, 2006: 667ff ). 
4 Because artemisinin itself has physical properties such as poor bioavailability 
that limit its effectiveness, semi-synthetic derivates of artemisinin have been 
developed. The primary derivate is dihydroartemisinin. Three others are 
drawn from it: artesunate, artemether, and arteether (Hien and White, 1993). 
The new derivate named artemisone was recently developed (Haynes et al., 
2006). Due to the very short half-life of artemisinin derivatives, their use as 
monotherapy requires a multiple dose regimen of seven days duration. It is 
assumed that the combination with a longer half-life ‘partner’ antimalarial 
drug allows a reduction in the duration of artemisinin treatment, while at the 
same time reducing the likelihood of resistance development to the partner 
drug.
The most common ACT-treatment is Coartem® (arthemeter-lumefantrine, 
AL); other combinations are artesunate-mefloquine (AS+MQ), artesunate-
amodiaquine (AS+AQ), and artesunate-sulphadoxine-pyrimethamine 
(AL+SP) (WHO, 2001b; Bekanis, 2004). For a comprehensive review of 
ACT formulations see Nosten and White, 2007 and Dalrymple, 2008: 19).
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5 Exceptions are the anthropological studies provided by Elisabeth Hsu (1999; 
2001; 2002; 2006a+b; 2009).
6 Results are based on 14 months of fieldwork. Research methods included 
participant observation, semi-structured, open-ended interviews, expert 
interviews, group discussions, as well as my involvement in various community 
projects that promote the use of Artemisia at household-level. I conducted 
qualitative interviews with Artemisia-consumers (41 patients, Malaria and 
HIV/Aids), staff members of Action for Natural Medicine (Anamed) (14), 
medical (including Chinese) practitioners using Artemisia-products (10), 
traditional healers (9), church leaders (8), local NGOs promoting Artemisia 
(6), national representatives such as WHO, NIMR, COSTECH, ITM, 
MoH, TFDA,TPI, UDSM (15), artemisinin producers such as BEEPZ, 
AA Ltd, TechnoServe (4), small-scale and commercial Artemisia-farmer (8). 
Regions involved: Mara, Mwanza, Tanga, Arusha, Iringa, Dar es Salaam, 
Kenya (Athi River). 
7 Supporter of the Artemisia-tea believe in its synergistic activity as found in 
the whole plant extracts. Artemisia contains different classes of compounds. 
At least 28 monoterpenes, 30 sesquiterpenes, 12 triterpenoids and steroids, 
36 flavonoids, 7 coumarins, 4 aromatic, and 9 alipathic compounds. Several 
of these have antimalarial activity; the most active being the sesquiterpene 
lactone artemisinin. As Artemisia´s antimalarial activity is attributable to 
a complex mixture of constituents, it is believed that the application of 
the whole-leaf Artemisia tea makes the development of the resistance less 
probable compared to a single agent as found in its chemical derivates (see 
Willcox et al., 2004:51; Willcox et al., 2009: 103f ).
8 All names used in this paper are synonyms. 
9 Piece of printed cotton fabric.
10 Possible side-effects that are listed for Coartem® are signs of an allergic 
reaction such as: exanthema, hives, difficulty breathing, and swelling of the face, 
lips, tongue, or throat. Other side-effects are: worsening malaria symptoms, 
dizziness, fainting, fast or pounding heartbeat, severe or uncontrolled 
vomiting or diarrhea, stomach pain, dark urine, clay-colored stools, jaundice 
(yellowing of the skin or eyes), weakness, mild headache, joint or muscle pain, 
and insomnia. See: [http://www.zct-berlin.de/neueinfuehrungen/arthemeter.
html]; [http://www.rxlist.com/coartem-drug-patient.htmsideeffects]. Accessed: 
15.2.2009.
11 Details for demand and supply of ACTs are given by Dalrymple, 2008: 13ff. 
12 An extraction facility in Kenya (Athi River) carries out both crude extraction 
and purification of artemisinin. It is designed to process up to 4 000 tons of 
Artemisia-leaves, to purify up to 60 tons of crude artemisinin, and to produce 
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20 tons of pure artemisinin per year (Haynes et al., 2006; Dalrymple, 2008: 
18). 
13 Results are based on personal communication with small-scale and 
commercial Artemisia-farmer in Tanzania´s northern plantations. 
14 For a more comprehensive (and critical) examination of how ‘efficacy’ has 
been conceived in medical anthropology, see for example (Etkin, 1988:300f ), 
(Nichter, 1992:226), and (Waldram, 2000:603ff ).
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